Study Evaluating Safety of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Elderly Subjects
NCT ID: NCT00500266
Last Updated: 2011-09-16
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
1053 participants
INTERVENTIONAL
2008-05-31
2009-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)
NCT00546572
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
NCT00521586
Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults
NCT03760146
Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Elderly Subjects
NCT00500357
Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults
NCT00744263
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
13-valent Pneumococcal Conjugate Vaccine
13-valent Pneumococcal Conjugate Vaccine (13vPnC)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
13-valent Pneumococcal Conjugate Vaccine (13vPnC)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Determined by medical history, physical examination, and clinical judgment to be eligible for the study
* Documented vaccination with 1 or more doses of pneumococcal vaccine at least 3 years before study enrollment
Exclusion Criteria
* Documented S pneumoniae infection within the past 5 years.
* Known or suspected immunodeficiency or receiving treatment with immunosuppressive therapy including cytotoxic agents or systemic corticosteroids
* Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that in the investigator's opinion precludes the subject from participating in the study.
68 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Wyeth
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Monitor
Role: STUDY_DIRECTOR
Wyeth is now a wholly owned subsidiary of Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chandler, Arizona, United States
Glendale, Arizona, United States
Phoenix, Arizona, United States
Phoenix, Arizona, United States
Rolling Hills Estates, California, United States
Apopka, Florida, United States
Boynton Beach, Florida, United States
Chiefland, Florida, United States
Gainesville, Florida, United States
Largo, Florida, United States
Melbourne, Florida, United States
West Palm Beach, Florida, United States
Atlanta, Georgia, United States
Atlanta, Georgia, United States
Arkansas City, Kansas, United States
Newton, Kansas, United States
Wichita, Kansas, United States
Wichita, Kansas, United States
Crescent Springs, Kentucky, United States
New Orleans, Louisiana, United States
Nitchitoches, Louisiana, United States
Camillus, New York, United States
Rochester, New York, United States
Raleigh, North Carolina, United States
Akron, Ohio, United States
Canal Fulton, Ohio, United States
Columbus, Ohio, United States
Franklin, Ohio, United States
Portland, Oregon, United States
Pittsburgh, Pennsylvania, United States
Goose Creek, South Carolina, United States
Mt. Pleasant, South Carolina, United States
Houston, Texas, United States
San Antonio, Texas, United States
Salt Lake City, Utah, United States
Salt Lake City, Utah, United States
West Jordan, Utah, United States
Bellingham, Virginia, United States
Walla Walla, Washington, United States
Wenatchee, Washington, United States
Berlin, , Germany
Berlin, , Germany
Berlin-Wilmersdorf, , Germany
Charlottenburg, , Germany
Deggingen, , Germany
Frankfurt am Main, , Germany
Hanover, , Germany
Kassel, , Germany
Leipzig, , Germany
Offenbach, , Germany
Wangen, , Germany
Würzburg, , Germany
Arlöv, , Sweden
Gothenburg, , Sweden
Skene, , Sweden
Skivarp, , Sweden
Stockholm, , Sweden
Umeå, , Sweden
Uppsala, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
6115A1-3000
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.